4篇
您的检索式：作者名="ELENA COMINO"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Application of the Analytic Hierarchy Process and the Analytic Network Process for the assessment of different wastewater treatment systems显示文摘 | Marta Bottero Elena Comino Vincenzo Riggio | 2011 | Italy Environmental Modelling ~ Software2011，，26： | 1 |
| 2 | Application of the Analytic Hierarchy Process and the Analytic Network Process for the assessment of different wastewater treatment systems显示文摘 | MARTA BOTTERO ELENA COMINO VINCENZO RIGGIO | 2011 | Environmental Modelling & Software2011，26，： | 1 |
| 3 | Exploring the environmental value of ecosystem services for a river basin through a spatial multicriteria analysis显示文摘 | Elena Comino Marta Bottero Silvia Pomarico Maurizio Rosso | 2014 | Land Use Policy2014，，： | 1 |
| 4 | Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet显示文摘BACKGROUND The gluten-free diet(GFD)has limitations,and there is intense research in the development of adjuvant therapies.AIM To examine the effects of orally administered Aspergillus niger prolyl endopeptidase protease(AN-PEP)on inadvertent gluten exposure and symptom prevention in adult celiac disease(CeD)patients following their usual GFD.METHODS This was an exploratory,double-blind,randomized,placebo-controlled trial that enrolled CeD patients on a long-term GFD.After a 4-wk run-in period,patients were randomized to 4 wk of two AN-PEP capsules(GliadinX;AVI Research,LLC,United States)at each of three meals per day or placebo.Outcome endpoints were:(1)Average weekly stool gluten immunogenic peptides(GIP)between the run-in and end of treatments and between AN-PEP and placebo;(2)celiac symptom index(CSI);(3)CeD-specific serology;and(4)quality of life.Stool samples were collected for GIP testing by ELISA every Tuesday and Friday during run-ins and treatments.RESULTS Forty patients were randomized for the intention-to-treat analysis,and three were excluded from the per-protocol assessment.Overall,628/640(98.1%)stool samples were collected.GIP was undetectable(<0.08μg/g)in 65.6%of samples,and no differences between treatment arms were detected.Only 0.5%of samples had GIP concentrations sufficiently high(>0.32μg/g)to potentially cause mucosal damage.Median GIP concentration in the AN-PEP arm was 44.7%lower than in the run-in period.One-third of patients exhibiting GIP>0.08μg/g during run-in had lower or undetectable GIP after AN-PEP treatment.Compared with the run-in period,the proportion of symptomatic patients(CSI>38)in the AN-PEP arm was significantly lower(P<0.03).AN-PEP did not result in changes in specific serologies.CONCLUSION This exploratory study conducted in a real-life setting revealed high adherence to the GFD.The AN-PEP treatment did not significantly reduce the overall GIP stool concentration.However,given the observation of a significantly lower prevalence of patients with severe symptoms in the AN-PEP arm,further clinical research is warranted. | Juan Pablo Stefanolo Verónica Segura Martina Grizzuti Abel Heredia Isabel Comino Ana Florencia Costa Roberto Puebla María Paz Temprano Sonia Isabel Niveloni Gabriel de Diego María E Oregui Edgardo Gustavo Smecuol Mauricio C de Marzi Elena F Verdú Carolina Sousa Julio César Bai | 2024 | World Journal of Gastroenterology2024，30，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员